DE-CSC
CSC , a world leader in business, legal, tax, and domain security, today released new research from their Digital Brand Services (DBS) division warning consumers that simple URL typos could lead to significant online fraud, counterfeit goods, and cyber crime during the holiday shopping season. The company identified and analyzed registered domain typos (misspellings) associated with the 10 largest online shopping brands in the world and found that over 70% of the 1,553 registered domain typos appear to be owned by third parties.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005233/en/
According to CSC’s new research , these third-party owned domains receive over five million visitors annually. In addition, 40% of these domains are using domain privacy services to mask or hide their ownership and identity, and close to 48% are configured with MX (mail) records that can be used for phishing and to intercept email. In its blog, CSC offers tips to both brand owners and consumers to protect themselves against fraudulent web properties and content.
A deep dive of the top 100 most visited typo domains shows they are being used in this manner:
- 38% are pointing to advertising-related and pay-per-click web content, which can be used to spread malware via domain parking services
- 27% had no live web content, yet 37% were configured to send and receive email with MX records
- 15% were engaged in affiliate referrals, which means the brand owner could be targeted for unauthorized affiliate activity resulting in loss of revenue
- 12% were pointing at shopping-related web content, which indicates that consumers could engage with nefarious retailers selling counterfeit goods while brand owners lose revenue
- 8% were pointing toward malicious web content e.g., malware
During the holiday shopping season, just one hour of downtime can cost a business over $500,000 in lost revenue*. Despite this, many global eCommerce and shopping companies are still lacking basic domain security measures that could prevent this from happening. For instance, only 16% of the top 500 global eCommerce and shopping domains leverage domain name system (DNS) hosting redundancy, which could secure their online presence from a distributed denial of service (DDoS) attacks. In addition, only 18% use registry locks that prevent DNS hijacking attacks that could redirect consumers to alternate websites. Lastly, 40% of retailers do not use enterprise-class domain registrars. This is partially explained by the fact that 40% of the observed domains still rely on retail registrars that typically don’t provide advanced domain security features.
“ In light of the global pandemic, both consumers and leading brands have embraced online shopping as we head into the 2020 holiday season. As such, we wanted to call attention to how brands and consumers are at increased risk for a multitude of threat vectors associated with online fraud, counterfeits, revenue leakage and many other cyber criminal activities this year,” says Ihab Shraim, chief technology officer for CSC. “As evidenced by the sheer number of mail-in votes in the U.S. election, consumers are looking for safe alternatives to in-person interactions, and it’s important for brands to not only provide those digital channels, but also ensure they are secure from online threat vectors.”
“We’re delighted that companies like CSC are advocating for companies and online brands to put the necessary security protocols in place to protect not only their brand reputation, but their consumers, from online fraud and cyber crime,” says Daniel Eliot, director of Education and Strategic Initiatives at the National Cyber Security Alliance (NCSA). “The NCSA's mission is to educate consumers and businesses about these credible risks, and the importance of using recommended cyber security best practices. CSC’s research is also an important part of advocating for consumers, and showing the pervasive risk of these cyber attacks and fraudulent domains.”
Additional resources:
- Blog post
- Consumer tips infographic
*gremlin.com/ecommerce-cost-of-downtime/
About CSC
CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system, digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201117005233/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press release
Based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s DATROWAY is the first and only medicine to significantly improve overall survival versus chemotherapy in this patient population If approved, DATROWAY could become the standard of care in this setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Produc
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press release
SteQeyma™45mg and 90mg solution for injection via autoinjector (pre-filled pen) receives positive CHMP opinion, which will facilitate subcutaneous administration in patients with plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD)1The new autoinjector option increases convenience, enhances individual patient experience and expands administration options Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
